Although AMPK is traditionally known for suppressing anabolic processes and promoting catabolism to inhibit cardiac hypertrophy (76), emerging evidence suggests it also supports selective anabolic programs in the heart that promote long-term adaptation and survival. The gene discussed is PRKAA2; the disease is cardiac hypertrophy.